5 results on '"Bachmeier, Christina A"'
Search Results
2. Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel.
- Author
-
Faramand, Rawan, Jain, Michael D., Staedtke, Verena, Bai, Renuyan, Kotani, Hiroshi, Reid, Kayla, Lee, SaeBom, Chavez, Julio C., Shah, Bijal D., Nishihori, Taiga, Lazaryan, Aleksandr, Khimani, Farhad, Liu, Hien, Bachmeier, Christina A., Dam, Marian, Brandjes, Brigett, Mullinax, John E., Gonzalez, Ricardo, Wang, Xuefeng, and Hussaini, Mohammed
- Subjects
- *
FERRITIN , *T cells , *B cells , *CELLULAR therapy , *CANCER treatment , *NEUROTOXICOLOGY , *CLINICAL trials , *ALEMTUZUMAB - Abstract
CAR T cells have been extensively investigated using constructs targeting CD19+ B cells for lymphoid malignancies demonstrating efficacy (Neelapu NEJM 2018; Schuster NEJM 2018). One of the main challenges of adoptive T cell therapy are immune mediated toxicities of cytokine release syndrome (CRS) and neurotoxicity (NT). Despite impressive objective response rates, durable responses are only seen in approximately 40% of patients treated in the pivotal axicabtagene ciloleucel (axi-cel) and tisagenlecleucel trials, highlighting the need for better understanding of the mechanisms of toxicity and efficacy. We aimed to evaluate the association of early biomarkers with severe toxicity and day 90 outcomes in patients treated with commercial axi-cel in a real world setting. Seventy-five patients treated with commercial axi-cel were included in this analysis. Baseline characteristics are summarized in Table 1. Patient serum samples were collected at baseline (within 30 days of conditioning chemotherapy), and then daily thereafter starting at the day of axi-cel infusion. Serum cytokine samples were analyzed using the Ella multiplex assay system. Cytokines analyzed include IL1b, IL2, IL6, IL15, TNFa, IFNg, Angiopoietin 1 and 2, as well as CRP and ferritin. Toxicities were graded daily using ASTCT consensus guidelines and retrospectively confirmed. Outcomes were evaluated at day 90 by the treating physician according to the International Working Group Response Criteria for Malignant lymphoma. P values were calculated using Wilcoxon rank sum test. We observed that baseline levels of CRP (p=0.0018) and Angiopoietin 2/1 ratio (p=0.0092) were associated with grade ≥3 [n=16] neurotoxicity Figure 1A-B). Baseline elevated levels of CRP (p=0.0413) and Ferritin (0.0264) were associated with more grade ≥3 CRS [n=16] (Figure 1C-D). Baseline elevated levels of CRP(p=0.0016), ferritin(p=0.0096) and IL6 (p=0.0029) were associated with poor outcomes at D90 defined as stable disease, progressive disease or death (Figure 1E-G). We demonstrate that baseline biomarker profile can identify patients at highest risk of developing severe toxicity and/or and treatment resistance highlighting the need to validate these findings in prospective studies. Patients in this poor outcome cohort may benefit from clinical trials evaluating prophylactic agents or more combination therapies to ameliorate severe toxicities or increase response rates. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience.
- Author
-
Hashmi, Hamza, Mirza, Abu-Sayeef, Darwin, Alicia, Logothetis, Constantine, Garcia, Franco, Kommalapati, Anuhya, Bachmeier, Christina A., Benson, Kaaron, Chavez, Julio C., Shah, Bijal D., Pinilla-Ibarz, Javier, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Davila, Marco L., Nishihori, Taiga, Jain, Michael D., and Locke, Frederick L.
- Subjects
- *
CHIMERIC antigen receptors , *RITUXIMAB , *B cells , *BLOOD coagulation factors , *T-cell lymphoma , *FIBRINOGEN , *LYMPHOMAS - Abstract
Hypofibrinogenemia can occur after Chimeric Antigen Receptor (CAR) T-cell therapy and is sometimes associated with cytokine release syndrome. Hypofibrinogenemia is associated with increased risk of bleeding as well as thrombosis. Limited literature exists on the incidence, complications and management of hypofibrinogenemia after CAR T-cell therapy. We analyzed medical records on 148 patients who received CD19-directed CAR T-cell therapy for large B-cell lymphomas between 05/2015 and 09/2019. All patients who had at least one serum fibrinogen level measured in the first 30 days after CAR T-cell infusion were included in the analysis. All patients with serum fibrinogen < 200 mg/dL [lowest normal value] had data collected on abnormalities in other coagulation parameters including PTT, PT, INR at the time of nadir serum fibrinogen level. Out of 148 patients, 35 had at least one serum fibrinogen level measured in the first 30 days after CAR T-cell infusion. Nadir serum fibrinogen was < 200 mg/dl in 15/35 patients: 0-100 mg/dl in 9/15 and 100-200 mg/dl in 6/15. At the time of nadir fibrinogen level, 2/15 patients had abnormalities seen in the other 3 coagulation parameters. Of the 15 patients that had serum fibrinogen level < 200 mg/dl, four had a bleeding event and one had a thrombotic event within first 30 days after CAR T-cell infusion but none of these patients had a low fibrinogen level at the time of the bleed. Given concern for increased risk of bleeding, patients with serum fibrinogen level less than 100 mg/dl were given cryoprecipitate infusions. Details of the abnormalities in the coagulation parameters are highlighted in the table. This study describes in detail, hypofibrinogenemia seen in patients treated with CD19-directed CAR T-cell therapy in lymphoma. None of the patients experienced a major bleeding or thrombotic event with low serum fibrinogen level. These descriptive data may be used by clinicians to inform their management of hypofibrinogenemia seen in CAR T-cell patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience.
- Author
-
Mirza, Abu-Sayeef, Hashmi, Hamza, Darwin, Alicia, Garcia, Franco, Kommalapati, Anuhya, Logothetis, Constantine, Bachmeier, Christina A., Chavez, Julio C., Shah, Bijal D., Pinilla-Ibarz, Javier, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Davila, Marco L., Nishihori, Taiga, Locke, Frederick L., and Jain, Michael D.
- Subjects
- *
CHIMERIC antigen receptors , *EXUDATES & transudates , *INTERLEUKIN-27 , *ASCITIC fluids , *IMPLANTABLE catheters , *LYMPHOMAS , *B cells - Abstract
In patients with lymphoma, third space fluid accumulations may develop or worsen during cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. Pre-existing symptomatic pleural effusions were excluded by the ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) for large B cell lymphoma (LBCL) and variants. The optimal management of effusions that develop before or after axi-cel infusion in LBCL is unknown. We performed a single center retrospective study evaluating 148 patients receiving CD19 CAR T-cell therapy for LBCL between 05/2015 and 09/2019. We identified all patients who developed pleural, pericardial and peritoneal effusions before (pre-CAR-T) or during the first 30 days after CAR T-cell infusion (post-CAR-T). Clinically relevant effusions were considered symptomatic based upon physician documentation. Total effusions and symptomatic effusions were noted in 24% (36/148) and 18% (27/148) of patients, respectively. Among 27 patients with symptomatic effusions, 59% (16/27) were pre-CAR-T effusions, 52% (14/27) persisted after day 30, and 44% (12/27) were malignant effusions. Overall, 67% of symptomatic effusions (18/27) were managed with diuretics, 44% (12/27) with a therapeutic thoracentesis or paracentesis and 33% (9/27) were observed with only supplemental oxygen provided. Six patients required pleural or abdominal catheters with a median indwelling duration of 54 (range, 29, 202) days, although 2 of these patients passed away with these indwelling catheters. Among symptomatic effusions developing only post-CAR-T (n=11), time to onset of effusion was median of 5 (range, 2-11) days and none of these patients required interventional drainage. Table 1 differentiates between effusions based on whether they were present (n = 19) or not (n = 17) prior to CAR T cell infusion. Nearly half of all effusions diagnosed in patients receiving CAR T cell therapy develop after infusion but most can be medically managed. Patients with pre-CAR-T effusions may require procedural drainage or indwelling catheters, as these effusions may persist beyond the acute CRS period. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. O1-1-1 Prediction of toxicity in R/R DLBCL treated with Axicabtagene Clioleucel (19-28z CAR T).
- Author
-
Kotani, Hiroshi, Faramand, Rawan, Lee, Sae Bom, Yu, Bin, Morrissey, Dylan, Locke, Frederick L, Jain, Michael D, Chavez, Julio C, Wang, Xuefeng, Mishra, Asmita, Bachmeier, Christina A, Brentjens, Renier J, Yoo, Sarah, Park, Jae H, and Davila, Marco L
- Subjects
- *
CHIMERIC antigen receptors , *BLOOD proteins , *BLOOD protein electrophoresis , *BURKITT'S lymphoma , *LYMPHOBLASTIC leukemia , *B cells - Abstract
Background A cytokine release syndrome (CRS) or neurotoxicity described as a chimeric antigen receptor (CAR) T Related Encephalopathy Syndrome (CRES) is one of the main complications while CD19 CAR T has been successful in relapsed/refractory (R/R) B cell malignancies. CRS and/or CRES have been associated with standard biomarkers such as CRP and ferritin but also with cytokines. We report the results of cytokine analysis using a point of care (POC) device to predict immune-related toxicities in patients with R/R DLBCL treated with axicabtagene ciloleucel (axi-cel). Methods Patients treated with commercial axi-cel in Moffitt Cancer Center were included in this study. Serum samples were collected prior to lymphodepleting chemotherapy at baseline and then during hospitalization. Based on 38 serum cytokineś analysis in B-cell acute lymphoblastic leukemia patients treated with 19-28z CAR T and results of published studies, 8 serum proteins were selected to monitor. CRS and CRES were prospectively graded by Lee criteria and CARTOX respectively. Results 41 patients were identified. Median age was 64 years old (76% male). Non-severe (grade 0-2) and severe (grade 3-5) CRS were observed in 93% and 7% respectively while non-severe and severe CRES were observed in 71% and 29% respectively. 2 patients died in the setting of severe toxicity. Baseline CRP, ferritin, IL-6 levels were significantly elevated in the patients who developed severe CRS and/or CRES. Baseline angiopoietin-2/angipoietin-1 ratio (ANG-2/1) was also correlated with severe CRES. In select cases, monitoring of cytokines provided clinical insight that wasńt evident from standard biomarkers. Conclusions We observed correlations between severe toxicities and elevated serum cytokine levels of baseline IL-6 and ANG-2/1 suggesting that these biomarkers may be utilized to predict severe toxicity in patients treated with CAR T. Monitoring of cytokines using a POC device is feasible and would be useful clinically. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.